Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 183 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Women Contraception Clear all

Conditions: Tubal Sterilization, Women's Health, Contraception, Contraception Behavior, Reproductive Behavior
Interventions: "My Decision" tubal sterilization decision aid, Usual Care; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: San Francisco, California • Knoxville, Tennessee

Conditions: IUD, Analgesia, Patient Preference, Pain, Acute
Interventions: TENS (transcutaneous electrical nerve stimulation) unit, Standard care; Device · Other
Lead sponsor: Tufts Medical Center; Other
Eligibility: 12 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Contraception
Interventions: Laparoscopic tubal ligation, Hysteroscopic sterilization; Procedure
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 19,317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Pregnancy (Unwanted), Sexually Transmitted Disease (STD), HIV Infection, Sexual Behavior
Interventions: #TranscendentHealth, Universal Sexual Health Program; Behavioral
Lead sponsor: Center for Innovative Public Health Research; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 467 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Clemente, California

Conditions: Contraception, Sexually Transmitted Infections, Cervical Cancer
Interventions: Community health worker; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 2,267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Contraception, Female Contraception
Interventions: DR-102; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 2,858 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 52
States / cities: Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Conditions: Opiate Addiction, Pregnancy, Contraceptive Behavior, Sexual Behavior
Interventions: Nexplanon (etonogestrel contraceptive implant), Standard postpartum contraceptive care; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Method of Contraception, Preterm Birth Recurrence
Interventions: Focused contraception counseling; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 14 Years to 50 Years · Female only
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Women, Female Contraception
Interventions: NES-E2 CVR; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 385 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more

Conditions: Female Sexual Dysfunction, Polycystic Ovary Syndrome
Interventions: Vitamin D, Hormonal contraception; Dietary Supplement · Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Dayton, Ohio • Hershey, Pennsylvania

Conditions: Contraception, Healthy Female
Interventions: Ulipristal acetate; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 14 more

Conditions: Healthy
Interventions: AZD6140, Levonorgestrel and Ethinyl Estradiol (Nordette®); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Contraceptive Usage
Interventions: TVU; Device
Lead sponsor: Bayer; Industry
Eligibility: 21 Years to 44 Years · Female only
Enrollment: 547 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2023
U.S. locations: 13
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 10 more

Conditions: Women With an ENG Contraceptive Implant
Interventions: removal of ENG implant, continuation of ING implant; Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Contraception
Interventions: Misoprostol, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Contraception
Interventions: Household Visits, Small Groups, Adopt-a-Friend; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 15 Years and older
Enrollment: 3,825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Contraception, Inhalation of Nitrous Oxide
Interventions: In-office Transcervical Sterilization (Essure®), Standard Oral pain medications, Intramuscular Ketorolac, Placebo pills, Oxygen, Nitrous Oxide; Procedure · Drug · Other
Lead sponsor: University of New Mexico; Other
Eligibility: 21 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception
Interventions: Non-hormonal period, Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg; Other · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Contraception
Interventions: Levonorgestrel IUS (Mirena, BAY86-5028); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 49
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 44 more

Conditions: Systemic Lupus Erythematosus, Contraception
Interventions: HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention, Routine Care; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pregnancy Prevention
Interventions: Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo; Drug · Other
Lead sponsor: InnovaGyn, Inc.; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Contraception
Interventions: Etonogestrel contraceptive implant; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Sacramento, California • Denver, Colorado • Philadelphia, Pennsylvania

Conditions: Alcohol Exposed Pregnancy
Interventions: Motivational Interviewing plus feedback, Video, Informational Brochure; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Charlottesville, Virginia • Richmond, Virginia

Conditions: Pregnancy, Contraception
Interventions: TV-46046 - 400 mg/mL, TV-46046 - 200 mg/mL; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Norfolk, Virginia

Search by objective public record fields.

"My Decision" Tubal Sterilization Decision Support Tool

TENS Unit for Analgesia During IUD Insertion

Retrospective Claims Analysis of Hysterectomy After Sterilization

#TranscendentHealth: A Text Messaging Pregnancy Prevention Program for Transgender Boys

Connecting Healthy Women: Examining the Effect of an Intervention From the Effect of Being Reachable

A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy

Immediate Postpartum Nexplanon Placement in Opioid Dependent Women

Optimizing Postpartum Contraception in Women With Preterm Births

Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring

Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction

Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

AZD6140 Oral Contraceptive Interaction Study

Essure Transvaginal Ultrasound (TVU) Study

Identification and Removal of the Non Palpable Etonogestrel Contraceptive Implant

Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women

Tipping Point: Using Social Network Theory to Accelerate Scale and Impact

Nitrous Oxide for Pain Management During In-office Transcervical Sterilization

Contraceptive Hormones and Women With Cystic Fibrosis

Mirena Extension Trial

The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

Nexplanon Use in Women Primarily Choosing a Combined Oral Contraceptive

Reducing Alcohol Exposed Pregnancy Risk: EARLY Randomized Controlled Trial

Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle